Novel presentation of SCN5A nonsense mutation as SCN5A overlap syndrome

Hyo-Jeong Ahn, MD,* So-Ryoung Lee, MD, PhD,* Jangsup Moon, MD, PhD,†‡ Eue-Keun Choi, MD, PhD,*§ Seil Oh, MD, PhD, FHRS*§

From the *Division of Cardiology, Department of Internal Medicine, Seoul National University Hospital, Seoul, Republic of Korea, †Department of Neurology, Seoul National University Hospital, Seoul, Republic of Korea, ‡Department of Genomic Medicine, Seoul National University Hospital, Seoul, Republic of Korea, and §Department of Internal Medicine, Seoul National University College of Medicine, Seoul, Republic of Korea.

Introduction
SCN5A is a gene with 28 exons encoding the pore-forming ion-conducting α-subunit of the cardiac voltage-gated sodium channel (Na1.5).1,2 Na1.5 enables the initiation and propagation of action potentials throughout the myocardium and determines cardiac excitability and electrical conduction.3 Various SCN5A mutations have been associated with electrical disorders and equally important structural diseases of the heart: long QT syndrome (LQTS), Brugada syndrome (BrS), isolated conduction defect (Lev-Lenègre syndrome), multifocal ectopic Purkinje-related premature contractions, sick sinus syndrome, atrial fibrillation, and dilated cardiomyopathy. Although originally thought to code for distinct clinical entities, a single SCN5A mutation could result in the expression of mixed phenotypes. Therefore, multiple clinical features may coexist within a patient, which is referred to as SCN5A overlap syndrome.4,5 In this case, we describe a patient with SCN5A nonsense mutation (c.664C>T, p.Arg222Ter), previously classified as a pathogenic variant observed in both BrS and individuals tested for LQTS.6–8 displaying a wide spectrum of rhythm disturbances in conjunction with familial history.

Case report
A 46-year-old man presented at the emergency department (ED) for repetitive transient cyanosis and agonal respirations during sleep. He was reported to have a transient loss of consciousness and mild epigastric discomfort. Symptoms were relieved after several episodes of vomiting and defecation.

An electrocardiogram (ECG) showed several transient and different features during acute management at the ED: (1) a sinus rhythm with wide QRS complex followed by coved-type ST-segment elevation and a negative T wave extending into the inferior leads, prolonged PR and QTc intervals (254 ms and 535 ms, respectively), and right bundle branch block (Figure 1A); and (2) a sinus rhythm with narrow QRS complex with frequent premature ventricular complexes presenting superior axis, left bundle branch block pattern, positive lead I and aVL, and negative aVR, thus suspected to originate from right ventricular mid septum or moderator band (Figure 1B).5,10 After several hours, ventricular fibrillation (VF) spontaneously developed and was terminated by an external defibrillator shock at 100 J (Figure 1C).

Five years ago, he had experienced dyspepsia, nausea, and dizziness, followed by loss of consciousness with spastic limb movement while on an airplane. A thorough evaluation at the neurology department revealed no abnormal neurological findings. However, 10.5 seconds of sinus pause early in the morning and wide QRS tachycardia were confirmed on 24-hour Holter monitoring (Figure 1D). The minimum heart rate (HR) was recorded as 18 beats per minute (bpm) early in the morning, and the average HR was 52 bpm. Permanent pacemaker implantation was recommended; however, the patient was reluctant to undergo such treatment. Other than this admission history, he had reported no medical problems and was not taking any medication.

On his latest ED visit, serum potassium and magnesium levels were marginally lower than the normal cutoff values: potassium = 3.4 mmol/L and magnesium = 1.3 mEq/L. Coronary angiography and transthoracic echocardiography showed no structural and functional abnormalities, only a mildly dilated left atrium (anteroposterior diameter, 42 mm) and borderline left ventricular end-diastolic diameter (52 mm) were observed. During admission, various ECG abnormalities were observed: doubtful coved-type ST-segment elevation dipping into a negative T wave at right precordial leads (Figure 2A), and saddle-back-type ST-segment elevation dipping into a negative T wave at right precordial leads (Figure 2A), and saddle-back-type ST-segment elevation dipping into a negative T wave at right precordial leads (Figure 2A), and saddle-back-type ST-segment elevation dipping into a negative T wave at right precordial leads (Figure 2A), and saddle-back-type ST-segment elevation dipping into a negative T wave at right precordial leads (Figure 2A), and saddle-back-type ST-segment elevation dipping into a negative T wave at right precordial leads (Figure 2A), and saddle-back-type ST-segment elevation dipping into a negative T wave at right precordial leads (Figure 2A), and saddle-back-type ST-segment elevation dipping into a negative T wave at right precordial leads (Figure 2A), and saddle-back-type ST-segment elevation dipping into a negative T wave at right precordial leads (Figure 2A), and saddle-back-type ST-segment elevation dipping into a negative T wave at right precordial leads (Figure 2A), and saddle-back-type ST-segment elevation dipping into a negative T wave at right precordial leads (Figure 2A), and saddle-back-type ST-segment elevation dipping into a negative T wave at right precordial leads (Figure 2A), and saddle-back-type ST-segment elevation dipping into a negative T wave at right precordial leads (Figure 2A), and saddle-back-type ST-segment elevation dipping into a negative T wave at right precordial leads (Figure 2A), and saddle-back-type ST-segment elevation dipping into a negative T wave at right precordial leads (Figure 2A), and saddle-back-type ST-segment elevation dipping into a negative T wave at right precordial leads (Figure 2A), and saddle-back-type ST-segment elevation dipping into a negative T wave at right precordial leads (Figure 2A), and saddle-back-type ST-segment elevation dipping into a negative T wave at right precordial leads (Figure 2A), and saddle-back-type ST-segment elevation dipping into a negative T wave at right precordial leads.

KEYWORDS
SCN5A; SCN5A overlap syndrome; Nonsense mutation; Cardiac sodium channel; Channelopathy
(Heart Rhythm Case Reports 2022;8:209–213)

Funding Sources: The authors have no funding sources to disclose. Conflict of Interest: The authors have no conflicts to disclose. Address reprint requests and correspondence: Dr So-Ryoung Lee, Department of Internal Medicine, Seoul National University Hospital, 101 Daehak-ro, Jongno-gu, Seoul, 03080, Republic of Korea. E-mail address: minerva1368@gmail.com.
We reported a novel clinical presentation of a known pathogenic mutation of SCN5A (c.664C>T, p.Arg222Ter) with a family history encompassing various transient electrocardiogram (ECG) features of long QT syndrome, Brugada syndrome, sick sinus syndrome, conduction abnormalities, atrial fibrillation, and marginally increased left ventricular cavity size.

Several modifiers, including age, sex, and co-inherited genetic variants, may explain the various disease expression and penetrance in overlap syndrome.

The same genetic variant may be expressed as an entirely different phenotype from one patient to another, requiring different approaches for proper management. Therefore, it is essential to appreciate various surface ECG presentations for accurate diagnosis, risk stratification, and tailored treatment strategies.

Figure 1 Various electrocardiogram presentations in 1 patient with SCN5A variant (c.664C>T, p.Arg222Ter) during initial evaluation: A: sinus rhythm with right bundle branch block, prolonged PR and QTc intervals; B: frequent premature ventricular complexes; C: ventricular fibrillation; and D: sinus pause with wide QRS tachycardia.
node dysfunction with bradycardia, various conduction defects, intermittent prolonged QT interval, Brugada signature ECG, AF, and ventricular arrhythmia (VF)—we were able to diagnose him with SCN5A overlap syndrome with a known pathogenic nonsense mutation.

In line with his diagnosis, he had a family history of cardiac arrhythmia. His mother in her mid-40s underwent pacemaker implantation owing to sick sinus syndrome. His older brother presented with sinus bradycardia and syncope, but no further electrocardiogram abnormalities were confirmed. His sister presented with sinus rhythm, HR of 61, and concomitant bifascicular block (right bundle branch block and left anterior fascicular block). A targeted genetic test of SCN5A was performed on his sister, and a pathogenic variant of SCN5A (c.664C>T, p.Arg222Ter, heterozygote) was also discovered. Figure 3 and Supplemental Figure 1 illustrate a pedigree of the family with the individual genetic test and electrocardiogram results of the patient’s brother and sister.

**Discussion**

In this case, we reported a novel clinical presentation of a known pathogenic mutation of SCN5A (c.664C>T, p.Arg222Ter) encompassing various transient ECG features of LQTS, BrS, sick sinus syndrome, conduction abnormalities, AF, and marginally increased left ventricular cavity size. The patient initially complained of vague epigastric discomfort and dizziness but eventually presented with VF years later. During admission, the patient exhibited transient and characteristic ECG features that prompted clinicians to establish the diagnosis. Considering the cardiac evaluation and a genetic test together with the patient’s history, we

![Figure 2](image1.png) Various electrocardiogram presentations in 1 patient with SCN5A variant (c.664C>T, p.Arg222Ter) during follow-up: A: type I Brugada pattern, B: type II Brugada pattern, and C: atrial fibrillation.

![Figure 3](image2.png) Pedigree and electrocardiograms of the patient’s family. +: SCN5A (c.664C>T, p.Arg222Ter) carrier. ICD = implantable cardioverter-defibrillator; NA = not available for genetic information; SSS = sick sinus syndrome.
diagnosed the patient with SCN5A overlap syndrome with a noted nonsense mutation.

In 1999, a multigenerational study of a Dutch family provided the first evidence that a single SCN5A mutation (1795 insD mutation) could result in an overlap syndrome of cardiac sodium channel diseases.4,5 In the following years, extensive combinations of phenotypes and related SCN5A mutations have been identified, and several explanations of simultaneously merged manifestations in a single mutation have been suggested. Loss- and gain-of-Na1,5-function (representative phenotypes are BrS and LQTS, respectively) features are apparent at different phases of the action potential, and the accompanying disruption of sodium currents varies according to the altered gene function. Depending on the existing HR, the subsequent availability of voltage-dependent sodium channels changes, and the dominant phenotype can be switched from one to the other. This putative underlying mechanism was verified in both computational and mouse models.11,12 SCN5A c.664C>T, p.Arg222Ter mutation is a nonsense mutation in exon 6 and is observed in individuals tested for LQTS and 1 with BrS.6–8 Although in vitro recapitulation of the patient’s mixed phenotypes was not provided, we introduced a case enabling further exploration of SCN5A and interpretation of the cardiac sodium channel.

An intriguing aspect of this clinical vignette is that his first-degree relatives (sister and brother), 1 of which was found to carry the same genetic variant of SCN5A, had no noticeable ECG findings other than sinus bradycardia and clinically insignificant conduction abnormality (bifascicular block). This family demonstrated varying disease severity: asymptomatic mutation carrier (sister), sinus bradycardia with syncope history (brother), sick sinus syndrome with pacemaker implantation (mother), and VF arrest case (index patient). Several modifiers have been investigated to influence the disease expression and penetrance in overlap syndrome. Age, sex, and exogenous factors, such as body temperature or electrolyte disturbances, could be potential clinical determinants of disease.13 Moreover, genetic modifiers and coexistence of compound mutations or single nucleotide polymorphisms may contribute to the diverse phenotypes among individuals with the same variant.1 However, it remains unclear why 1 phenotype predominates or which combination of phenotypes become apparent in a patient with a particular mutation. In this case, we performed Sanger sequencing and multiplex ligation–dependent probe amplification of target genes based on the patient’s clinical symptoms. Therefore, any coexistence of compound mutations of single nucleotide polymorphisms could not be evaluated, and confirmation of possible genetic modifiers that might explain varying disease severity in the family is limited.

It is important to appreciate various surface ECG presentations within an individual for accurate diagnosis, risk stratification, and tailored treatment strategies. For example, the risk of lethal ventricular arrhythmias is higher in LQTS type 3 with the existence of additional multifocal ectopic Purkinje-related premature contractions than in patients with LQTS type 3 alone.14 In addition, the various diseases stemming from SCN5A mutations have distinct responses to different antiarrhythmic drugs. For example, beta blockers are well known to be efficient for LQTS type 1; mexiletine and ranolazine are considered promising drugs in LQTS type 3; and quinidine is the drug of choice for BrS.15 The same genetic variant may be expressed as an entirely different phenotype from one patient to another, requiring different approaches for proper management. Therefore, clinicians should not only determine the genetic mutation of cardiac channels present in a patient, but also discern its manifestations for a profound understanding of the disease and delivering optimal care.

Conclusion
We introduced a novel clinical case of a known pathogenic variant of SCN5A (c.664C>T, p.Arg222Ter) displaying various ECG presentations: a VF episode, prolonged QT interval, BrS, sick sinus syndrome, conduction abnormalities, and AF. Moreover, the patient’s family showed varying disease expressivity and severity. The clinical spectrum of SCN5A mutations is broad, and patients often exhibit transient SCN5A abnormalities. Overt diagnostic changes can be missed in concealed and intermittent forms. Therefore, approaching varying ECGs with a high index of suspicion, precise interpretation, and incorporation of molecular study results is of paramount importance in the treatment of cardiac sodium channelopathy patients.

Appendix
Supplementary data
Supplementary data associated with this article can be found in the online version at https://doi.org/10.1016/j.hrcr.2021.12.014.

References
1. Remme CA, Wilde AA, Bezzi CA. Cardiac sodium channel overlap syndromes: different faces of SCN5A mutations. Trends Cardiovasc Med 2008; 18:78–87.
2. Wilde AAM, Amin AS. Clinical spectrum of SCN5A mutations: long QT syndrome, Brugada syndrome, and cardiomyopathy. JACC Clin Electrophysiol 2018;4:569–579.
3. Remme CA. Cardiac sodium channelopathy associated with SCN5A mutations: electrophysiological, molecular and genetic aspects. J Physiol 2013; 591:4099–4116.
4. Bezzi C, Veldkamp MW, van Den Berg MP, et al. A single Nat+ channel mutation causing both long-QT and Brugada syndromes. Circ Res 1999; 85:1206–1213.
5. van den Berg MP, Wilde AA, Vieroua TJW, et al. Possible bradycardic mode of death and successful pacemaker treatment in a large family with features of long QT syndrome type 3 and Brugada syndrome. J Cardiovasc Electrophysiol 2001; 12:630–636.
6. Asadi M, Foo R, Bhuiyan ZA, et al. Genetic analysis of cardiac SCN5A gene in Iranian patients with hereditary cardiac arrhythmias. Anatol J Cardiol 2016; 16:170–174.
7. Kaplinger JD, Tester DJ, Salisbury BA, et al. Spectrum and prevalence of mutations from the first 2,500 consecutive unrelated patients referred for the FAMILION long QT syndrome genetic test. Heart Rhythm 2009;6:1297–1303.
8. Selga E, Campuzano O, Pinsach-Abuin ML, et al. Comprehensive genetic characterization of a Spanish Brugada syndrome cohort. PLoS One 2015;10:e0132888.
9. Enriquez A, Baranchuk A, Briceno D, Saenz L, Garcia F. How to use the 12-lead ECG to predict the site of origin of idiopathic ventricular arrhythmias. Heart Rhythm 2019;16:1538–1544.
10. Segal OR, Chow AW, Wong T, et al. A novel algorithm for determining endocardial VT exit site from 12-lead surface ECG characteristics in human, infarct-related ventricular tachycardia. J Cardiovasc Electrophysiol 2007;18:161–168.
11. Clancy CE, Rudy Y. Na(+) channel mutation that causes both Brugada and long-QT syndrome phenotypes: a simulation study of mechanism. Circulation 2002;105:1206–1213.
12. Remme CA, Verkerk AO, Nuyens D, et al. Overlap syndrome of cardiac sodium channel disease in mice carrying the equivalent mutation of human SCN5A-1795insD. Circulation 2006;114:2584–2594.
13. Robyns T, Nuyens D, Van Casteren L, et al. Reduced penetrance and variable expression of SCN5A mutations and the importance of co-inherited genetic variants: case report and review of the literature. Indian Pacing Electrophysiol J 2014;14:133–149.
14. Barake W, Giudicessi JR, Asirvatham SJ, Ackerman MJ. Purkinje system hyperexcitability and ventricular arrhythmia risk in type 3 long QT syndrome. Heart Rhythm 2020;17:1768–1776.
15. Postema PG, Neville J, de Jong JS, Romero KA, Wilde AA, Woosley RL. Safe drug use in long QT syndrome and Brugada syndrome: comparison of website statistics. Europace 2013;15:1042–1049.